A significant regulatory milestone has been reached for ozone based medical waste treatment. Viking Ozone Technology has received a formal Attestation of Conformity from France’s national metrology and testing laboratory, Laboratoire national de métrologie et d’essais, known as LNE, for its VKIN 300 SD infectious waste pretreatment system. Announced on November 3, 2026, the decision confirms that the specified equipment meets the applicable French requirements for disinfection pretreatment of infectious healthcare waste. For hospitals, waste management providers and technology developers, the development highlights the growing importance of independently evaluated alternatives for handling hazardous medical materials.
What the French conformity decision means
The attestation was issued on October 28, 2026, under reference number 41506 0. It applies to the VKIN 300 SD configuration and confirms compliance with the requirements identified in the assessment, including French standard NF X 30 503 1:2024. The document is valid through October 27, 2031, and may be renewed once, subject to the applicable conditions.
LNE is France’s national laboratory for metrology and testing. Its work includes technical assessment, testing and conformity services across a range of industries. In this case, its assessment provides an independent reference for a specific medical waste treatment system and a defined set of French requirements. That distinction matters: a conformity attestation is not simply a company statement that a product works. It records the outcome of an assessment against specified technical and regulatory criteria.
The decision follows a process that has taken several years. Viking Ozone, an indirect majority owned subsidiary of Viking Global Technologies, had been pursuing French conformity documentation after submitting its equipment for testing and evaluation. The company shipped a VKIN 300 unit to France in January 2025 as part of that process. The formal attestation now marks completion of a major step for the certified configuration.
How the VKIN 300 uses ozone to treat infectious waste
Healthcare facilities generate waste that can contain infectious materials, contaminated supplies and other items requiring controlled handling. Before such waste can move into an approved disposal or downstream management process, it may need treatment to reduce biological hazards. The challenge is practical as well as technical: facilities need systems that can process waste reliably while protecting workers, patients, nearby communities and the environment.
The VKIN 300 is designed to pretreat regulated medical and biohazardous waste using ozone as its disinfection agent. Ozone is a highly reactive form of oxygen. Under controlled conditions, it can damage microorganisms through oxidation, making it useful in certain disinfection applications. The system combines an ozone treatment process with monitoring and control functions intended to manage operating conditions and maintain treatment records.
The French attestation identifies a minimum average ozone concentration of 3,500 parts per million during a 45 minute treatment cycle for the certified process. These parameters are part of the specific conformity assessment and should not be interpreted as a universal treatment recipe for every type of medical waste or every ozone based system. Actual performance depends on factors such as waste composition, equipment configuration, operating conditions and compliance with the relevant procedures.
Independent testing examined treatment performance
The conformity process included laboratory evaluation under the French standard. The accompanying evaluation report records satisfactory findings across several assessment areas, including biological indicator treatment, infectious waste treatment, microbial regrowth, airborne microbial contamination and particle size testing.
These areas address different parts of the treatment challenge. Biological indicators help assess whether a disinfection process can inactivate selected test organisms under defined conditions. Testing for microbial regrowth considers whether organisms may return after treatment. Airborne contamination assessments examine potential biological risks associated with the treatment environment, while particle size testing contributes to evaluating how waste is processed.
For healthcare operators, this kind of evidence is important because safe waste management cannot depend on a machine’s headline performance claim alone. Facilities need clear operating procedures, staff training, maintenance schedules, monitoring records and a reliable process for handling material before and after treatment. Independent testing can support purchasing and compliance decisions, but it does not remove the need for careful site management.
Why the milestone matters for healthcare waste management
Medical waste management is a public health responsibility that continues after a patient leaves a hospital room or a clinical procedure ends. Used dressings, contaminated disposable equipment and other infectious materials must be separated, contained, transported and treated through appropriate systems. A failure at any stage can expose healthcare workers, waste handlers and the wider community to avoidable risks.
Traditional treatment options include autoclaving, which uses pressurized steam, and incineration, which relies on high temperatures. Each approach has operational requirements and environmental considerations. Autoclaves require suitable loading, temperature, pressure and cycle controls. Incineration requires emissions management and appropriate facilities. No single technology is automatically suitable for every waste stream or location.
Ozone based pretreatment offers another approach for applications where the process is technically appropriate and permitted by local rules. Its potential advantages must be weighed against practical questions such as energy use, ozone containment, operating costs, equipment maintenance, waste compatibility and the arrangements required for final disposal. A disinfection process does not necessarily make treated material suitable for ordinary municipal waste collection. The subsequent handling route remains subject to applicable waste regulations.
For hospitals and specialist waste contractors, the value of a new treatment option will ultimately depend on demonstrated reliability in real operating environments. They will need to understand throughput, staffing needs, service support, consumables, downtime and total operating costs. The French attestation gives the VKIN 300 SD a defined conformity reference, but customers will still need to evaluate whether the equipment fits their facilities and waste management obligations.
France provides a regulatory reference, not automatic global approval
The company has described the LNE decision as an important foundation for its commercialization plans in France and potentially other international markets. The achievement may help discussions with healthcare institutions, distributors and waste management organizations that require documented evidence of technical conformity before considering new equipment.
However, the scope of the attestation is specific. It covers the VKIN 300 SD configuration and the French requirements identified in the document. It does not amount to automatic regulatory approval across the European Union or in other countries. Other jurisdictions may apply different technical standards, environmental rules, licensing procedures and site specific requirements.
The attestation also depends on the equipment continuing to meet the applicable requirements. The document may be affected if relevant product requirements change or if the certified equipment is modified. Manufacturers and operators therefore need to maintain configuration control, technical documentation and appropriate quality procedures throughout the product’s service life.
Commercial progress will be the next test
With the conformity milestone achieved, Viking Ozone says it intends to advance discussions with prospective customers, distributors and strategic partners. That work will determine whether the regulatory achievement can lead to installations and sustained commercial activity.
Several practical questions remain. The company will need to demonstrate that it can manufacture and support the equipment at a scale that matches customer demand. Healthcare organizations will want clarity on installation requirements, operator training, maintenance arrangements and service response times. Prospective customers will also compare the system with established treatment methods, considering both the cost of purchasing equipment and the long term expense of running it.
Financing and customer acceptance are important considerations as well. A conformity attestation can reduce uncertainty about whether a defined system meets specified technical requirements, but it does not guarantee purchase orders, revenue or widespread adoption. Commercial deployment may require additional regulatory, site specific, installation and operating approvals, alongside sufficient manufacturing capacity and funding.
A meaningful step, with work still ahead
The French LNE attestation represents a concrete achievement for the VKIN 300 SD and a notable development in the medical waste treatment sector. It follows independent testing and confirms that the specified equipment meets the French requirements identified in its conformity documentation. For a technology intended to handle infectious healthcare waste, that kind of external assessment is an important part of building confidence.
Yet the wider significance will depend on what happens next. Healthcare providers need safe, dependable and economically practical ways to manage infectious waste. New technologies deserve serious consideration when supported by transparent testing, clear regulatory documentation and credible operating evidence. They must also demonstrate that they can perform consistently beyond the assessment environment.
As Viking Ozone moves toward commercialization, the key measures will be installations, operating performance, customer experience and compliance across the locations where the system is deployed. The attestation opens an important door in France. Turning that regulatory progress into lasting improvements in healthcare waste management will require disciplined execution, continued oversight and evidence from real world use.
Further information about the company’s announcement and regulatory milestone is available through Viking Global Technologies investor relations. Background on France’s national testing and metrology organization can be found at LNE’s official website.
